Most patients failing antiretroviral treatment in Uganda continue to fail their treatment
regimen even if a dominant drug-resistant HIV-1 genotype is not detected. In a recent …

Design: A retrospective study of consecutive sequence samples from 106 patients at one
institution with viral load (VL) of more than 400 copies/ml, with no change in ART for more …

Antiretroviral drug resistance in patients failing non‐nucleoside reverse transcriptase
inhibitor (NNRTI)‐based first‐line combination antiretroviral treatment (ART) is influenced …

Highly active antiretroviral therapy (HAART) has dramatically reduced mortality and
morbidity in HIV-infected persons in developed countries. Although the use of HAART …

Background Introduction of antiretroviral therapy (ART) in sub-Saharan Africa was a hot
debate due to many concerns about adherence, logistics and resistance. Currently, it has …

Objective: To assess the virological response, genotypic resistance profiles, and
antiretroviral plasma concentrations in HIV-2 antiretroviral-treated (antiretroviral therapy …

Although highly active antiretroviral therapy (HAART) is an effective treatment for HIV, many
physicians withhold this treatment from HIV-positive injecting drug users (IDUs) because of …

Objective (s): To investigate the relationship between detection of HIV drug resistance by 2
years from starting antiretroviral therapy and the subsequent risk of progression to AIDS and …

Background Increased access to antiretroviral therapy (ART) has resulted in rising levels of
pretreatment human immunodeficiency virus drug resistance (PDR). This is the first …

Background: In 1998, Senegal launched one of Africa's first antiretroviral therapy (ART)
programs. Since then, the number of treated patients in Africa has substantially increased …